Sugi Predict

Sugi Predict / Compounds / SCHEMBL131029

SCHEMBL131029

SCHEMBL131029

CC(C)CCCC(=O)OC(C)C

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.61
▸ CA1 P00915 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ GAA P10253 1/20 0.39
▸ EPHX2 P34913 1/20 0.39
▸ TSHR P16473 3/20 0.39
▸ PTPN1 P18031 1/20 0.39
▸ MAPT P10636 3/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ CASP1 P29466 1/20 0.38
▸ CASP7 P55210 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ BLM P54132 1/20 0.38
▸ KDM1A O60341 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15315589 0.93 LMNA (0.64) LMNACA1ALDH1A1GAAEPHX2
SCHEMBL27897917 0.91 LMNA (0.68) LMNACA1ALDH1A1GAAEPHX2
SCHEMBL28495155 0.91 LMNA (0.62) LMNACA1ALDH1A1GAAEPHX2
SCHEMBL25678965 0.91 LMNA (0.68) LMNACA1ALDH1A1GAAEPHX2
SCHEMBL28445534 0.91 LMNA (0.68) LMNACA1ALDH1A1GAAEPHX2
SCHEMBL23628387 0.91 LMNA (0.68) LMNACA1ALDH1A1GAAEPHX2
SCHEMBL8088310 0.91 LMNA (0.68) LMNACA1ALDH1A1GAAEPHX2
SCHEMBL14848943 0.91 LMNA (0.68) LMNACA1ALDH1A1GAAEPHX2
SCHEMBL9932904 0.91 LMNA (0.68) LMNACA1ALDH1A1GAAEPHX2
SCHEMBL27780141 0.91 LMNA (0.68) LMNACA1ALDH1A1GAAEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240218023-A1 CYCLIC PEPTIDE-N-ACETYLGALACTOSAMINE (GALNAC) CONJUGATES FOR DRUG DELIVERY TO LIVER CELLS MICROBIO (SHANGHAI) CO., LTD. (CN) 2024-07-04 — — US disclosed
US-20240218011-A1 GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF FIREFLY BIO, INC. 2024-07-04 — — US disclosed
US-20240066047-A1 ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-02-29 — — US disclosed
US-20230399356-A1 ANTIBODY DRUG CONJUGATES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-12-14 — — US disclosed
US-11725024-B2 Antibody drug conjugates TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-08-15 — — US disclosed
US-11685761-B2 Cyclic di-nucleotide compounds as sting agonists MERCK SHARP & DOHME LLC (US) 2023-06-27 — — US disclosed
US-11666594-B2 Antibody-drug conjugates comprising a cyclic dinucleotide TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-06-06 — — US disclosed
CN-111647975-A Novel spandex oil agent and spandex obtained through treatment of novel spandex oil agent 烟台锐泽化学品有限公司 2020-09-11 — — CN disclosed
US-20180002346-A1 AZOLOBENZAZINE COMPOUNDS, COMPOSITIONS COMPRISING THESE COMPOUNDS AND THEIR USE FOR CONTROLLING INVERTEBRATE PESTS BASF SE (DE) 2018-01-04 — — US disclosed
CN-107129547-A Ingredient of solid catalyst, catalyst and application for olefinic polymerization 中国石油化工股份有限公司 2017-09-05 — — CN disclosed
US-9631086-B2 Use of polymers as additives in a polymer matrix UNIVERSITÉ DE BORDEAUX (FR) 2017-04-25 — — US disclosed
US-20170044206-A1 CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS MERCK SHARP & DOHME CORP. (US) 2017-02-16 — — US disclosed
US-8450319-B2 Pyrrolopyridazinone compound UBE INDUSTRIES, LTD. (JP) 2013-05-28 — — US disclosed
EP-1982986-B1 PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR UBE INDUSTRIES (JP) 2012-03-07 — — EP disclosed
US-20090036453-A1 Pyrrolopyridazinone Compound UBE INDUSTRIES, LTD. (JP) 2009-02-05 — — US disclosed
EP-1982986-A1 PYRROLOPYRIDAZINONE COMPOUND Ube Industries, Ltd. (JP) 2008-10-22 — — EP disclosed
CN-85109197-A method for producing polymer — 1986-05-10 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240066047-A1 ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE STING1, TLR9, CGAS LMNA 3423/4885CA1 4577/4885ALDH1A1 3598/4885
US-20240218011-A1 GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF NR3C1, NR3C2, MC2R LMNA 4639/4885CA1 4523/4885ALDH1A1 3778/4885
US-20180002346-A1 AZOLOBENZAZINE COMPOUNDS, COMPOSITIONS COMPRISING THESE COMPOUNDS AND THEIR USE FOR CONTROLLING INVERTEBRATE PESTS DDT, CRY1, TH LMNA 2671/4885CA1 2652/4885ALDH1A1 2080/4885
US-20240218023-A1 CYCLIC PEPTIDE-N-ACETYLGALACTOSAMINE (GALNAC) CONJUGATES FOR DRUG DELIVERY TO LIVER CELLS GALNT1, CSGALNACT1, GALNT2 LMNA 1541/4885CA1 762/4885ALDH1A1 1251/4885
US-20230399356-A1 ANTIBODY DRUG CONJUGATES STING1, CGAS, TBK1 LMNA 4539/4885CA1 4828/4885ALDH1A1 4494/4885
US-11666594-B2 Antibody-drug conjugates comprising a cyclic dinucleotide STING1, TLR9, CGAS LMNA 3423/4885CA1 4577/4885ALDH1A1 3598/4885
US-20170044206-A1 CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS STING1, CGAS, IFNAR1 LMNA 1670/4885CA1 4630/4885ALDH1A1 4183/4885
US-20090036453-A1 Pyrrolopyridazinone Compound CBR3, CBR1, CYC1 LMNA 1679/4885CA1 2208/4885ALDH1A1 580/4885
US-11725024-B2 Antibody drug conjugates STING1, CGAS, TBK1 LMNA 4539/4885CA1 4828/4885ALDH1A1 4494/4885
US-11685761-B2 Cyclic di-nucleotide compounds as sting agonists STING1, CGAS, IFNAR1 LMNA 1653/4885CA1 4564/4885ALDH1A1 4105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.